americanus [30]. While C-terminally truncated versions of full-length H. americanus orcokinin-family peptides, including Orc[1-12] and Orc[1-11] ( Fig. 2A), detected in XO/MT extract ( Fig. 3C) and direct tissue ( Fig. 3A and B) spectrum, have been also been reported by our laboratory [10] and by other researchers [4], [6], [10], [27] and [40], the alanine-containing peptide

sequence is unusual because an alanine residue at this position is not known for any full-length orcokinins detected mass spectrometrically or predicted from genomic information. When we analyzed the extract from an entire eyestalk ganglion, we again detected peaks for the m/z 1270.57, putative Orc[Ala11], peptide (see Fig. 3D). To ensure that the detection of this peptide was not the result of a mutation specific to the individual animal analyzed, localized tissue samples and entire eyestalk ganglia from additional individuals RO4929097 clinical trial (n > 30) were extracted. Although the abundance

of the m/z 1270.57 and other putative Orc[Ala11]-derived peaks varied relative to that of other detected peptides, signals for this peptide were consistently observed, except in extracted sinus gland samples, where these signals were weak or missing. To further characterize the amino acid sequence of the peptide appearing at m  /z   1270.57, we subjected the peak to analysis by SORI-CID, the form of MS/MS used on our FTMS instrument. Isolation of the [M+H]+ Angiogenesis inhibitor at m  /z   1270.57 from an eyestalk ganglion extract followed by SORI-CID yielded a spectrum showing an abundant peak at m  /z   1253.54 (loss of NH3) and the production of y-type sequence

ions, including the Asp-Xxx cleavage products at y8, y8o, and y5 (m/z 894.43, 876.42, and 537.28, respectively; see Fig. 4A). This experiment provided support for our assignment of the m/z 1270.57 peak as an ionized orcokinin family peptide and, furthermore, supported our attribution of the m/z 1253.54, 894.43, 876.42, and 537.28 peaks in the MALDI-FT mass spectrum of tissue extracts to this gas-phase precursor. However, the SORI-CID mass spectrum did not provide sufficient information to establish the full amino acid sequence. In previous studies [43], we have shown that the variable C-terminal Liothyronine Sodium sequence of orcokinin-family peptides can be established by using the mass spectrometric isolation and dissociation of the yn+1 fragment by SORI-CID. The yn+1 fragment, produced via Asp-Xxx cleavage, contains the arginine (R) residue at the N-terminus and yields b-type sequence ions, which retain the N-terminal, arginine-containing, end of the peptide sequence. When the y5 peak at m/z 537 was isolated and subjected to SORI-CID interrogation, we measured peaks, including b1, b2-NH3, b3, and b4 at m/z 157.11, 227.11, 301.16, and 448.23, respectively, that are consistent with the sequence RSGF ( Fig. 5A). Other peaks in the spectrum (m/z 472.23, 489.26, 502.24) resulted from combinations of small neutral molecule losses (NH3, H2O, and CH2O).